FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed are: a pharmaceutical combination for treatment of proliferative disease, which contains Hsp90 inhibitor ethamide 5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid (AUY922) and mTOR inhibitor, representing everolimus (RAD001), a respective method of treating proliferative disease and a set for the same purpose.
EFFECT: synergic antiproliferative effect of the combination on cells of different types of cancer is demonstrated.
5 cl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS CONTAININS Bcr-Abl/c-Kit/PDGF-RTK INHIBITORS FOR TREATING CANCER | 2007 |
|
RU2452492C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS FOR CANCER TREATMENT | 2007 |
|
RU2449788C2 |
| COMBINATIONS OF THERAPEUTIC AGENTS APPLICABLE FOR TREATING CANCER | 2007 |
|
RU2447891C2 |
| COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| TREATING TUBEROUS SCLEROSIS | 2007 |
|
RU2473343C2 |
| COMBINATION OF PYRIMIDYLAMINOBENZAMIDE AND mTOR KINASE INHIBITOR | 2006 |
|
RU2443418C2 |
| PHARMACEUTICAL COMBINATIONS CONTAINING PYRIDO[4,3-d]PYRIMIDINE DERIVATIVES AS HSP90 INHIBITOR AND HER2 INHIBITOR | 2009 |
|
RU2532375C2 |
| SOME CHEMICAL STRUCTURES, COMPOSITIONS AND METHODS | 2009 |
|
RU2513636C2 |
| TREATING NEUROENDOCRINE TUMOURS | 2006 |
|
RU2487711C2 |
